drugset / Trial / NCT01311882

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

NCT01311882

Phase 1 Completed 28 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

This is a study to evaluate next-day residual effects of MK-4305 on highway driving performance in healthy, non-elderly participants.

Timeline

Start
2011-04
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg
Subject Suvorexant Small molecule 40 mg
Comparator Zopiclone Small molecule 7.5 mg

Indications